Address
1 Corporate Drive
South San Francisco, CA 94080

Contact
contact@soley.ai

Soley Evaluation Platform

Proprietary Platform to Decode the Cellular Language for Efficient Drug Discovery

We Have Questions. Cells Hold the Answers.

As cells sense their environment, they display global cellular responses as feature-rich images known as Cellular Language. Our proprietary platform allows us to decode Cellular Language, enabling unprecedented application of anticipatory biology to evaluate molecules and predict cell fate.

Soley Evaluation Platform

Proprietary, validated, high-throughput: >100K molecules evaluated weekly

Cellular Sensing & Anticipatory Biology

Cells Sense Molecules & Forecast Future Outcomes

Breakthrough Productivity

Discovered three lead series of compounds in 14 months

We have established a growing pipeline for both oncological and non-oncological implications backed by reproducible, high-quality data.

Revolutionizing Drug Discovery

Graded Cellular Language correlates with clinical disease severity. Our proprietary platform technology transcends the capabilities of cell painting. Our highly sensitive, mechanistically driven process allows us to track and monitor hundreds of proteins and their movements. 

This enables our nuanced modulation toward cell death vs. rejuvenation, which spotlights potential drug candidates.

Published Example of Dynamic Cellular Stress Biomarker:

Direct Cells Toward Increased Stress

(oncology and infectious disease applications)

Group 332
Group 33211
image 1
image 2
image 3
image 4
image 5
image 6
Group 333
Group 33311

Direct Cells Toward Decreased Stress

(neurodegenerative, muscular dystrophy and numerous other applications)

Soley has demonstrated in-vitro/in-vivo correlations in the following diseases:

Alzheimer’s

Parkinson’s

Tauopathy and other
neurodegenerative disorders

Muscular dystrophy

Myocardial infarction
and stroke

Others

Rooted in Science. Scaling with Tech.

While cells speak for themselves, we use the power of AI/ML to augment human intelligence and understanding of Cellular Language at every stage of the drug discovery and development process. Using our established AI/ML infrastructure, we are able to generate our own high-quality, reproducible data, exponentially furthering productivity. 

Our Science

Our work revolves around the notion that cells are the most powerful computers ever created. Our scientific process, combined with the power of AI/ML, help us gain fluency in this cellular language and revolutionize drug discovery.

Our science

Pipeline

Soley Therapeutics is unveiling multiple near-term value catalysts across biopharma and tech arms.

Pipeline

Dan Von Hoff, M.D.

  • 30+ years pioneer in oncology drug development
  • Distinguished Professor and Physician in Chief, Translational Genomics Research Institute
  • Professor of Medicine at University of Arizona and Mayo Clinic
  • Former National Cancer Advisory Board Member
  • Past President of the American Association for Cancer Research
  • Contributed to development of Abraxane®(nab-paclitaxel), Camptosar® irinotecan, Gemzar® gemcitabine and many other

Afsaneh Naimollah

Linkedin
  • 30+ years of experience corporate finance, strategy advisory and investment banking
  • Executive in Residence, Plug and Play Tech Center
  • Managing Partner, XEN Partners
  • Former Global Head of Barclays Capital Technology Group

Leo Grady, PhD

Linkedin
  • 20+ years of industry experience leading AI/ML, computer vision, and digital health tech
  • Founder and CEO, Stealth AI healthcare company
  • Former CEO of PaigeAI
  • Former SVP of Engineering, Heartflow
  • Founder and CEO of Jona
  • CEO in Residence at Breyer Capital

Fei-Fei Li, PhD

Linkedin
  • Sequoia Professor of Computer Science, Stanford University
  • Co-Director, Stanford Human Centered AI Institute
  • Creator of ImageNet
  • Co-Founder, Chairperson of the Board, AI4ALL
  • Former Chief Scientist of AI/ML, VP Google

Peter Libby, MD

Linkedin
  • Mallinckrodt Professor of Medicine, Cardiovascular Specialist, Harvard Medical School and Brigham and Women’s Hospital
  • World renowned expert in atherosclerosis, cardiovascular medicine and clonal hematopoiesis of indeterminate potential

Keith Flaherty, MD

  • Professor of Medicine, Harvard Medical School
  • Director of Clinical Research, Cancer Center, Massachusetts General Hospital
  • 25+ years expertise in oncology research, drug development, and targeted cancer therapies
  • Co-founder of Loxo Oncology, X4-Pharma, Strata Oncology, Apricity Oncology, Scorpion Therapeutics

Clay Johnston, MD, PhD

Linkedin
  • Professor of Neurology
  • Inaugural Dean, Dell Medical School, UT Austin
  • Former Associate Vice Chancellor of Research, UCSF
  • Co-Founder, Harbor Health

Tony Adamis, MD

  • 30+ years of industry R&D experience
  • Former SVP, Development Innovation, Genentech
  • Co-discovery of VEGF in ocular disease
  • Co-founder, Director, EyeBio

Antoine Yver, MD

Linkedin
  • 30+ years experience and world leader in oncology drug development
  • Board Member, Sanofi
  • Former Head of Oncology Global Medicine Development, AstraZeneca
  • Former Chairman of Development, Centessa
  • Former EVP, Global Head of Oncology R&D, Daiichi Sankyo
  • Contributed to development of Tagrisso® osimertinib, Lynparza® olaparib, Enhertu® trastuzumab deruxtecan and many other

Dan Von Hoff, MD

Co-Founder, CEO, Board Member

Linkedin
  • 30 years of academic experience in patient care, teaching, clinical/basic and stem cell research
  • Expertise in physiologic cellular stress, stem cells, cardiomyocytes, and neuronal cells
  • The Johns Hopkins School of Medicine (1995): M.D.
  • Harvard Medical School / Brigham and Women’s Hospital (1995-2003): internship, residency, chief residency, general and interventional cardiology
  • UCSF (since 2003): Translational Cardiac Stem Cell Program: Founder and Director